FOLD Quote, Financials, Valuation and Earnings

Halozyme Therapeutics has a net margin of -4.76% compared to Amicus Therapeutics's net margin of 47.23%. Amicus Therapeutics's return on equity of -71.17% beat Halozyme Therapeutics's return on equity of 156.62%.

Amicus Therapeutics has a consensus price target of $17.33, signalling upside risk potential of 83.23%. On the other hand Halozyme Therapeutics has an analysts' consensus of $65.00 which suggests that it could grow by 20.91%. Given that Amicus Therapeutics has higher upside potential than Halozyme Therapeutics, analysts believe Amicus Therapeutics is more attractive than Halozyme Therapeutics.

Amicus Therapeutics has a beta of 0.618, which suggesting that the stock is 38.193% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.236, suggesting its more volatile than the S&P 500 by 23.598%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are smaller than Halozyme Therapeutics quarterly revenues of $290.1M. Amicus Therapeutics's net income of -$6.7M is lower than Halozyme Therapeutics's net income of $137M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Halozyme Therapeutics's PE ratio is 17.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.81x versus 7.37x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Immuneering has a net margin of -4.76% compared to Amicus Therapeutics's net margin of --. Amicus Therapeutics's return on equity of -71.17% beat Immuneering's return on equity of --.

Amicus Therapeutics has a consensus price target of $17.33, signalling upside risk potential of 83.23%. On the other hand Immuneering has an analysts' consensus of $12.42 which suggests that it could grow by 520.83%. Given that Immuneering has higher upside potential than Amicus Therapeutics, analysts believe Immuneering is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.618, which suggesting that the stock is 38.193% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Immuneering quarterly revenues of --. Amicus Therapeutics's net income of -$6.7M is higher than Immuneering's net income of -$14.6M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.81x versus 186.38x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -4.76% compared to Amicus Therapeutics's net margin of -236.04%. Amicus Therapeutics's return on equity of -71.17% beat Insmed's return on equity of --.

Amicus Therapeutics has a consensus price target of $17.33, signalling upside risk potential of 83.23%. On the other hand Insmed has an analysts' consensus of -- which suggests that it could grow by 34.28%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Amicus Therapeutics has a beta of 0.618, which suggesting that the stock is 38.193% less volatile than S&P 500. In comparison Insmed has a beta of 1.122, suggesting its more volatile than the S&P 500 by 12.219%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Insmed quarterly revenues of $93.4M. Amicus Therapeutics's net income of -$6.7M is higher than Insmed's net income of -$220.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.81x versus 29.79x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -4.76% compared to Amicus Therapeutics's net margin of -503.65%. Amicus Therapeutics's return on equity of -71.17% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

Amicus Therapeutics has a consensus price target of $17.33, signalling upside risk potential of 83.23%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $20.50 which suggests that it could grow by 2178.65%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Amicus Therapeutics, analysts believe Tonix Pharmaceuticals Holding is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.618, which suggesting that the stock is 38.193% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.016, suggesting its more volatile than the S&P 500 by 101.616%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Amicus Therapeutics's net income of -$6.7M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 5.81x versus 0.40x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.